Brain health expertise, reduced delivery risk

Complex eligibility criteria, specialist assessments, and caregiver involvement. Long study durations and demanding patient journeys. Every one of those raises operational risk.

Success depends on more than site capacity. It needs teams who understand the clinical reality behind the protocol and know how to navigate the nuances of every trial.

For more than 25 years NeuroClnx has specialised in brain health research, helping sponsors navigate complexity across neurodegenerative, psychiatric and emerging therapeutic areas.

NeuroClnx has vast experience with Alzheimer’s and dementia research. We’ve been leaders in this field for more than two decades and are one of Scotland’s leading Alzheimer’s clinical and research centres.

Our experience spans:

• Preclinical and prevention studies
• Mild cognitive impairment
• Early Alzheimer’s disease
• Disease-modifying therapies
• Long-term extension studies
• Caregiver-supported protocols

You get the support of teams experienced in recruiting, assessing and retaining participants through complex studies that often run for years.

Movement disorder studies demand specialist neurological expertise, nuanced patient assessment and sustained participant engagement.

Our capability in Parkinson’s disease and related movement disorders, including Huntington’s disease, is led by neurological investigators with decades of experience in the area.

Our teams know the realities of studying progressive neurological conditions, and how to support participants over the long haul.

Supporting sponsors in complex psychiatric research

Studies in anxiety, depression and mood disorders bring their own delivery challenges. Engagement can fluctuate. Symptoms can affect adherence. Holding retention takes a supportive and clinically sensitive approach.

We combine experienced psychiatric investigators with clinician-led delivery. Our teams understand how much participant engagement, continuity of care and consistent study conduct matter to retention, protocol adherence and data quality.

Dedicated patient liaison specialists, support robust follow-up processes and have long experience of extended brain health studies, and the result is a model designed to reduce participant burden while producing complete, reliable datasets.

NeuroClnx is your research partner that balances participant wellbeing with the operational discipline needed to deliver reliably.

Psychedelic studies demand specialist facilities, experienced clinical oversight, robust governance and a partner able to manage complex participant experiences safely and consistently.

We have invested in dedicated psychedelic research capability, including specialist dosing facilities, the regulatory approvals these studies require.

Our clinician-led approach puts participant safety, protocol adherence and operational control first. These therapies are an exciting area of innovation, but a successful study still rests on the fundamentals: reliable recruitment, strong engagement, quality data and consistent execution.

We are a partner that understands both the promise of these emerging therapies and the rigour needed to turn innovation into high-quality clinical evidence.